natgillin/translations-raw huggingface dataset:
The data obtained in this study show that the efficacy of the compound ST2087 is similar to that of the compound of origin ST1469 (ED50: 3.71 mg/kg corresponding to 9.11 umol/kg) (Table 2). 
Podaci koji su prikupljeni u ovom istraživanju pokazuju da je učinak spoja ST2087 jednak onom ishodišnog spoja ST1469 (EDgo: 3,71 mg/kg što odgovara 9,11 umol/kg) (Tablica 2).
Number of active transformers 2 3 
(21) Broj predmeta:
A suspension according to claim 8, characterized in that said non ionic surfactant is a polysorbate, a polyoxylated oil and/or a polyethylenglycol ether. 
Suspenzija u skladu s patentnim zahtjevom 1, naznačena time što je navedeni neionski surfaktant polioksilirano ulje i/ili polietilen-glikolski eter,
The method according to any one of claims 1 to 3, 5 to 9, 12 or 13, or the anti-VLA-4 therapy for use according to any one of claims 4 to 13, wherein the patient is determined to be at higher risk of developing PML if the patient has received anti-VLA-4 therapy for longer than 24 months and has not previously received a non-anti-VLA-4 immunosuppressant therapy. 
Postupak prema bilo kojem od zahtjeva 1-3, naznačen time što je pacijent klasificiran kao da ima viši rizik od PML-a ako je pacijent primao natalizumab duže od 24 mjeseca, te nije prethodno primao specificiranu ne-anti-VLA-4 imunosupresijsku terapiju, pri čemu je specificirana ne-anti-VLA-4 imunosupresijska terapija odabrana od mitoksantrona, metotreksata, azatioprina, ciklofosfamida, mikofenolata, anti-CD20 terapije, anti-CD11a terapije i mikofenolat mofetila.
a substituted starch having a degree of substitution of at least one substituent group; an inorganic phase; and water, wherein the inorganic phase, the substituted starch and the water are mixed together to form a mixture, the inorganic phase is at least partially hydrated by the water, and the degree of substitution and the at least one substituent group are selected such that the substituted starch is not soluble during mixing at a mixing temperature but at least partially dissolves as the temperature increases during processing of the mixture and forms a film substantially dispersed throughout the organic-inorganic composite wherein the organic-inorganic composite is substantially strengthened. 
supstituirani škrob koji nije topiv u hladnoj vodi, koji ima stupanj supstitucije između 1,5 i 2,5 masenih %, gdje je navedeni škrob supstituiran s najmanje jednom eterskom skupinom ili esterskom skupinom te ima maseni postotak krutina na viskozitetu od 1000 cps i na temperaturi od 65,6°C (150°F) u rasponu od 9 do 43%; voda; i anorganska faza koja sadrži gips, pri čemu je anorganska faza barem djelomično hidratizirana vodom, dok je supstituirani škrob prisutan kao film u biti raspršen kroz cijeli organsko-anorganski kompozit tako da se time organsko-anorganski kompozit bitno ojačava.
48). The cyclic peptide of the present invention (or the cyclic part thereof) may consist of at least 18 amino acids and of at most 25 amino acids. 
€) yje aminokiselina koja nije Cys, 1 gdje navedeni ciklički peptid se sastoji od najmanje 16, a najviše 25 aminokiselina i ima aminokiselinski slijed
The design of the tube makes it impossible for women to use this device by themselves in order to collect a sample from the cervix or from the endometrium. 
Izvedba ove cijevi ne omogućava ženama da same koriste ovu napravu kako bi prikupile uzorak iz grlića maternice ili uzorak sluznice maternice.
Again, it is assumed that at least in the final approach phase the first and second capsule enclosure member 9, 13 approach each other in a more or less translational trajectory. 
Nadalje se pretpostavlja da se najmanje u konačnoj fazi približavanja prvi i drugi element za obuhvaćanje čahure 9, 13 približe jadan drugom u manje ili više pravocrtnoj putanji.
A formulation comprising an aqueous carrier having a pH of 5.5 to 8.0 and a polypeptide comprising one or more single variable domains at a concentration of 1 mg/mL to 200 mg/mL, said formulation being formulated for administration to a human subject and said formulation further comprising a buffer at a concentration of 10mM to 100mM selected from histidine pH 6.0-6.5, wherein said formulation has an inorganic salt concentration of 150 mM or lower and wherein the polypeptide comprises at least one single variable domain directed against human serum albumin (HSA). 
Formulacija koja sadrži vodeni nosač koji ima pH od 5.5 do 8.0 i polipeptid koji sadrži jednu ili više pojedinačnih varijabilnih domena u koncentraciji od 1 mg/mL do 200 mg/mL, navedena formulacija formulirana je za davanje ljudskom subjektu i navedena formulacija nadalje sadrži histidinski pufer u koncentraciji od 10 mM do 100 mM, pH 6.0-6.5; pri čemu navedena formulacija ima koncentraciju anorganske soli od 150 mM ili nižu, pri čemu je polipeptid odabran od jedne od SEQ ID NO: 1 do 6 i pri čemu pH formulacije iznosi između 6.2 i 7.5.
further comprises a labeling group, wherein said labeling group is selected from the group consisting of isotopic labels, magnetic labels, redox active moieties, optical dyes, biotinylated groups and predetermined polypeptide epitopes recognized by a secondary reporter; 
(ii) nadalje sadrži grupu obilježivača, pri čemu je grupa obilježivač odabrana iz grupe koja se sastoji od izotopnih obilježivača, magnetskih obilježivača, redoks reaktivnih dijelova, optičkih boja, biotiniliranih grupa i predodređenih polipeptidnih epitopa koje prepoznaje sekundarni receptor;
It has a viscosity of 77cps @ 20°C on Brookfield viscometer with a LV1 spindle at 30rpm. The density is 1.224g/cm3 A ready-to-use composition for intramuscular or subcutaneous injection, comprising 15%-55% w/v penethamate hydroiodide and at least one oily vehicle including ethyl oleate; 
Pripravak spreman za upotrebu za intramuskularnu ili potkožnu injekciju, koji sadrži 15%-55% m/v penetamat hidrojodida i najmanje jedan uljasti nosač, uključujući etil oleat; naznačen time što je viskoznost pripravka ispod 3000 mPas pri temperaturi od 20%C i brzini smicanja od 1/s izmjereno metodom čaše s cilindrom.
Purification by column chromatography on silica gel with ethyl acetate/hexanes 1/5 afforded 2-chloro-3-methoxybenzaldehyde 7a (4.68 g, 94%) as a colorless oil, which solidified upon standing. 
Pročišćavanjem kromatografijom na stupcu silikagela, uz eluiranje smjesom etil-acetat/heksani_ 1:5 dobije se 2-klor-3-metoksibenzaldehid 7a (4,68 g, 94 %) u obliku bezbojnog ulja, koje se skrutne prilikom stajanja.
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein 
O Rs ili polimorf, solvat, tautomer, enantiomer ili njihova farmaceutski prihvatljiva sol, naznačen time da
The method of claim 12 wherein the agent is an interferon. 
Spoj prema patentnom zahtjevu 19, naznačen time što je sredstvo interferon.
The closed loop systems can include a reservoir containing a fast-acting insulin and a hyaluronan degrading enzyme, where the hyaluronan degrading enzyme is present in an amount sufficient to render the resulting combination a super fast-acting insulin composition. 
Sustav sa zatvorenim krugom za kontrolu nivoa glukoze u krvi kod subjekta, koji sadrži: brzo djelujući analog inzulina, pri čemu je brzo djelujući analog inzulina inzulin glulizin ili inzulin aspart, i enzim koji razgrađuje hijaluronan;
reacting a compound of Formula II: wherein X1 is chloro, bromo, or iodo, with a compound of Formula III: to form a compound of Formula I, or salt thereof; and 
reakciju spoja s formulom II: [image] pri čemu X1 je klor, brom, ili jod, sa spojem s formulom III: [image] da se dobije spoj s formulom I, ili njegova sol; i [image]
Architecture system of a local grid (10) according to claim 1, characterised in that said Logic H is of calculation of the energy availability or requirement of each node n and includes at least the following consequential Phases: 
Arhitektura sustava lokalne mreže (10) prema zahtjevu 1, naznačena time da je navedena Logika H za izračun raspoloživosti ili potražnje energije za svaki čvor n i uključuje barem sljedeće značajne Faze, kao što je prikazano u odgovarajućem dijagramu (slika 17):
The composition of claim 2, wherein the composition is for use in a method of treating or preventing uveitis, and wherein the composition is for use in a method of reducing or preventing retinal damage in uveitis. 
Sastav prema zahtjevu 3, gdje je sastav za upotrebu u postupku liječenja ili prevencije uveitisa, i gdje je sastav za upotrebu u postupku smanjenja ili prevencije oštećenja retine kod uveitisa.
Tool according to claim 1, characterised in that the face is a flat surface inside the periphery but outside the outlet, in operation the flat surface provides underpressure and suction effect of the tool toward the surface according to the venturi effect. 
Alat prema patentnom zahtjevu 1, naznačen time da je ploha za čišćenje ravna površina unutar oboda ali izvan ispusta, u radu ravna površina osigurava podtlak 1 efekt usisavanja Alata prema površini koju treba očistiti po principu Venturijevog efekta.
at least one gravimetric gradiometer (5); 
- < barem jedan gravimetrijski gradiometar (5)
Said pathologies according to the invention are preferably selected from among acne, seborrhoeic dermatitis, androgenetic alopecia, hirsutism, benign prostatic hyperplasia, forms of prostate cancer, male contraception, polycystic ovary syndrome, control of aggressive or aberrant sexual behaviours and syndrome of precocious puberty. 
Farmaceutski pripravak za primjenu prema patentnom zahtjevu 4 za liječenje akni, seboreičnog dermatitisa, androgenetske alopecije, hirzutizma, benigne hiperplazije prostate, oblika raka prostate, sindroma policističnih jajnika, sindroma preranog puberteta i kontrole agresivnog ili aberantnih seksualnih ponašanja.
a stabilizing fin; and 
stabilizirajuću peraju (200); i
the nitrite is present as a nitrite solution. 
(c) nitritje prisutan kao otopina nitrita.
In a specific embodiment, the genetically modified mouse is a mix of an aforementioned 129 strain and an aforementioned C57BL/6 strain. 
Genetski modificirani miš u skladu s patentnim zahtjevom 4, naznačen time, da je promotorski odsječak imunoglobulina promotorski odsječak humanog imunoglobulina.
The method of claim 1, wherein the compound is of Formula (Ig): 
[image] poželjno spoj ima Formulu (Ig):
The formulation of claim 1, wherein the formulation is in the form chosen from a gel, lotion, cream, spray, aerosol, ointment, emulsion, suspension, liposomal system, lacquer, patch, bandage, buccal tablet, sublingual tablet, suppository, vaginal dosage form or occlusive dressing. The formulation claim 22, wherein the form is a gel. 
Formulacija prema bilo kojem od zahtjeva 1 do 12, naznačena time, da je navedena formulacija u obliku gela, losiona, kreme, spreja, aerosola, masti, emulzije, suspenzije, liposomnog sustava, laka, flastera, zavoja, bukalne tablete, sublingvalne tablete, čepića, vaginalnog doznog oblika ili okluzivnog zavoja, te poželjno u obliku gela.
Composition for use according to claim 6, wherein the composition is applied and distributed on the floor in a dosage of 4-12 litres per m2, preferably 4-8 litres per m2. 
Sastav za korištenje prema zahtjevu 6, naznačen time da se sastav nanosi i raspodijeli na podu u dozi od 4 – 12 litara na m2, poželjno 4 – 8 litara na m2.
The compound according to any one of claims 1 to 7, or the pharmaceutically acceptable salt thereof or the solvate thereof, wherein R3a is hydrogen, lower alkyl optionally substituted by substituent group C, lower alkenyl optionally substituted by substituent group C, lower alkynyl optionally substituted by substituent group C, carbocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, carbocycleoxy lower alkyl optionally substituted by substituent group C, heterocycle lower alkyl optionally substituted by substituent group C, 
Spoj prema bilo kojem od zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time, da R** je vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, niži alkenil prema potrebi supstituiran sa supstituentskom skupinom C, niži alkinil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbocikliloksi niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom €,
In some embodiments, provided are 19-mer double-stranded nucleic acid molecule wherein the antisense strand is SEQ ID NO:127; and includes 2'OMe modified ribonucleotides at positions 3, 5, 9, 11, 13, 15, 17, and 19; a 2'-5'-ribonucleotide in position 7; and a C3OH non-nucleotide moiety covalently attached at the 3'-terminus; and the sense strand is SEQ ID NO:60 and includes five consecutive 2'-5'-ribonucleotides in the 3'-terminal positions 15, 16, 17, 18, and 19; a C3Pi non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic moiety covalently attached at the 5'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što protusmisleni lanac sadrži SEQ ID NO:127, a smisleni lanac sadrži SEQ ID NO:60; gdje protusmisleni lanac dodatno sadrži 2'-O- metilom modificirane ribonukleotide na položajima 1, 3, 5, 9, 11, 13, 15, 17, te 19; 2'-5'-ribonukleotid na položaju 7; 1 C3Pi-C30H nenukleotidni ostatak kovalentno vezan na 3'-kraju; te gdje smisleni lanac dodatno sadrži pet uzastopnih 2'-5'-ribonukleotida na 3'-terminalnim položajima 15, 16, 17, 18, te 19; C3Pi nenukleotidni ostatak kovalentno vezan na 3'-kraju; i imnvertirani nebazni ostatak kovalentno vezan na 5'-kraju.
Data provided by the person taking the sample can be applied to a container of this type. It has been found that a small quantity of sample is sufficient to obtain a representative result. 
Podaci koje je dala osoba koja je dobila uzorak mogu biti stavljeni na spremnik ovakve vrste, Bilo je nađeno da je mala količina uzorka dovoljna da se dobije reprezentativan rezultat.
Alternatively, alcohol (AG′) may be fluorinated using methods known to those skilled in the art, such as DAST [(diethylamino)sulfur trifluoride], to provide a fluoro compound which can be elaborated to its tetrazole derivative and deprotected using methods described herein. 
Alternativno, alkohol (AG') se može fluorirati uporabom metoda poznatih stručnjacima iz struke, poput DAST [(dietilamino)sumpor trifluorid], da bi se dobio fluoro spoj koji može biti elaboriran do svojeg tetrazol derivata i zatim se uklanja zaštita uporabom postupaka opisanih u ovom tekstu.
20 shows that the tensile strength for the PET container of the present invention exposed to ambient conditions varies from about 14,000 psi to 18,000 psi, with an average at about 17,000 psi. 
PET posuda iz patentnog zahtjeva 1 gdje zid posude ima sadržaj vlage od oko 1780 ppm do oko 1980 ppm kada je izložen uvjetima vrućeg punjenja na oko 96?
with a vinyl Grignard reagent, to obtain a compound of formula IIa in the form of diastereomeric mixture (S,R+R,R) 
S vinil Grignardovim reagensom, da bi se dobio spoj formule Ila u obliku dijastereoizomerne smjese (S, R+R, R)
A compound of formula I: wherein A is NH2; and B is H; or a pharmaceutically acceptable salt or hydrate thereof, for use in the inhibition of RNA viral polymerase in a human subject, wherein the RNA viral polymerase is a polymerase selected from the group consisting of orthomyxoviridae, bunyaviridae, flaviviridae, and filoviridae viral polymerases. 
Spoj formule I: [image] pri čemu A je NH2; i B je H; ili njegova farmaceutski prihvatljiva sol ili hidrat, namijenjen upotrebi u inhibiciji RNK viralne polimeraze kod subjekta, pri čemu je virusna RNK polimeraza:
Filtering the flow suctioned by the mobile suction means (5), with at least one filtration means (3); and Returning the filtered water to said at least one containing means (8); 
najmanje jedno sredstvo za filtriranje (3) koje je konfigurirano za filtriranje protoka vode koji sadrži nataložene čestice; najmanje jedna linija spajanja (15) povezana između navedenog najmanje jednog mobilnog sredstva za usisavanje (5) i navedenog najmanje jednog sredstva za filtriranje (3);
a light chain variable amino acid sequence of SEQ ID NO: 38 and a heavy chain variable amino acid sequence of SEQ ID NO: 33. 
varijabilnu sekvencu aminokiselina laganog lanca SEQ ID NO: 38 i varijabilnu sekvencu aminokiselina teškog lanca SEQ ID NO: 33.
Het1 is a 5-membered or 6-membered monocyclic aromatic heterocycle comprising 1 or 2 identical or different ring heteroatoms selected from the series consisting of nitrogen, oxygen and sulfur, which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C1-C4)-alkyl and (C1-C4)-alkyl-O-; 
Hetl je 5-eročlani ili 6-eročlani monociklički aromatski heterocikl, koji sadrži 1 ili 2 ista ili različita heteroatoma u prstenu, koje se bira iz skupine koju čine dušik, kisik i sumpor, koji je nesupstituiran ili je supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira iz skupine koju čine halogen, (C;-Cy)-alkil 1 (C;-C4)-alkil-O-,
The aqueous pharmaceutical suspension according to claim 7, wherein the wetting agent is, by weight/volume (g/100 mL), about 0.01% to about 0.05%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sredstvo za vlaženje iznosi, težinski/volumno (g/100 ml), otprilike 0,01 % do otprilike 0,05 %.
or, wherein the synthetic GLA adjuvant has the following structure: or a pharmaceutically acceptable salt thereof, wherein: 
i R4 su C9-20 alkil; ili, gdje sintetski GLA ima sljedeću strukturu:
a selecting device for selecting one of the circuit configurations resulting in a sufficiently accurate dividing ratio; and 
selekcijsko sredstvo (36) za odabiranje jedne od sklopnih konfiguracija koja rezultira s dovoljno preciznim omjerom dijeljenja;
Most preferable herbicide tolerant or herbicide resistant crops according to the invention are oilseed rape, canola (brassica napus). 
Najpoželjnije kulture koje podnose herbicid ili koje su otporne na herbicid prema izumu su uljana repica, kanola (Brassica napus).
0-20% of the metformin or a pharmaceutically acceptable salt thereof is released after 0.5 hour; 
Farmaceutski sastav sukladno bilo kojem od zahtjeva 1 - 6, pri čemu 0-20% metformina ili njegove farmaceutski prihvatljive soli se oslobađa nakon 0.5 sati;
A process for making a container according to any of claims 1 to 9, wherein the process comprises: 
Postupak izrade posuda prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu postupak sadrži:
An orally disintegrating tablet comprising less than or equal to 20 mg of a corticosteroid selected from the group consisting of fluticasone, budesonide, mometasone, and salts, solvates and esters thereof, wherein the orally disintegrating tablet disintegrates within 60 seconds in simulated saliva fluid when tested using the USP <701> Disintegration Test. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 6, koja sadrži manje ili jednako 20 mg budezonida ili njegovog solvata ili estera, i najmanje jedno sredstvo za raspršivanje, pri čemu se tableta razgrađuje unutar 60 sekundi u simuliranoj tekućini sline kada se testiranje provodi uporabom USP <701> Testa razgradnje.
The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R23 is alkoxy. 
11. Tvar iz patentnog zahtjeva 9, ili njena farmaceutski prihvatljiva sol, pri čemu je Bs
The rodent of claim 1, wherein the nucleotide sequence encoding a chimeric human/rodent MHC II a polypeptide is expressed under regulatory control of endogenous rodent MHC II a promoter and regulatory elements and/or the nucleotide sequence encoding a chimeric human/rodent MHC II B polypeptide is expressed under regulatory control of endogenous rodent MHC II B promoter and regulatory elements. 
U glodavca iz zahtjeva 1. nukleotidni slijed koji kodira kimerni MHC II a polipeptid čovjeka/glodavca izražava se pod regulacijskom kontrolom endogenog MHC II a. promotora glodavca 1 regulacijskih elemenata i/ili nukleotidni slijed koji kodira kimerni MHC II B polipeptid čovjeka/glodavca izražava se pod regulacijskom kontrolom endogenog MHC II f promotora glodavca i regulacijskih elemenata.
A device as claimed in claim 3, wherein the bearing is of a material of low friction coefficient. 
Uređaj (10) u skladu s patentnim zahtjevom 1, naznačen time što je ležaj (28) od materijala s niskim koeficijentom trenja.
A combination according to any one of claims 1 to 10 or a pharmaceutical composition according to claim 11 for the prophylaxis or treatment of a disease state or condition which is selected from a carcinoma of the bladder, breast, colon, kidney, epidermal, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, endometrium, thyroid, prostate, or skin, a hematopoietic tumour of lymphoid lineage, a hematopoietic tumour of myeloid lineage, thyroid follicular cancer, a tumour of mesenchymal origin, a tumour of the central or peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoctanthoma, thyroid follicular cancer, or Kaposi's sarcoma; breast cancer, ovarian cancer, colon cancer, prostate cancer, oesophageal cancer, squamous cancer and non-small cell lung carcinomas. 
Pripravak prema bilo kojem od zahtjeva 1 do 4 ili spoj prema bilo kojem od zahtjeva 5 do 9, za primjenu u profilaksi ili liječenju nekog bolesnog stanja ili bolesti iz skupine u koju spadaju karcinom mokraćnog mjehura, dojke, debelog crijeva, bubrega, epidermalni karcinom, karcinom jetre, pluća, jednjaka, žučnog mjehura, jajnika, gušterače, želuca, grlića maternice, sluznice maternice, štitnjače, prostate ili kože, hematopoetski tumor limfoidnog podrijetla, hematopoetski tumor mijeloidnog podrijetla, folikularni karcinom štitnjače, tumor mezenhimalnog podrijetla, tumor središnjeg ili perifernog živčanog sustava, melanom, seminom, teratokarcinom, osteosarkom, kseroderma pigmentosum, keratoktantom, folikularni karcinom štitnjače ili Kaposijev sarkom, karcinom dojke, karconom jajnika, karcinom debelog crijeva, karcinom jednjaka, karcinom skvamoznih stanica 1 nesitnostanični karcinomi pluća,
Immediate release or extended release can be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. 
Trenutno oslobađanje ili produženo oslobađanje može se postići primjenom prikladnih farmaceutskih sastava koji sadrže prikazane spojeve, ili, posebno u slučaju produženog oslobađanja, primjenom uređaja kao što su potkožni implanti ili osmotske pumpe.
said rotor (30) comprises a plurality of inner air ducts (36), each inner air duct (36) being configured to allow passage of an airflow therethrough, 
- < navedeni rotor (30) ima više unutarnjih vodova za zrak (36), gdje je svaki unutarnji vod za zrak (36) podešen da dopusti prolaženje zraka kroz sebe,
Thus, the disclosure provides an antibody that binds to an epitope recognised by an antibody having the variable heavy chain sequence recited in SEQ ID NO: 95, and the variable light chain sequence recited in SEQ ID NO: 109. 
(k) varijabilno područje slabog lanca od sekvence SEQ ID NO: 95, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 109;
treating Compound 9 with a lower alkyl carbonyl compound and a carbonate base in a biphasic solvent system to produce purified Compound 8; and 
tretman spoja 9 sa C1 do C6 alkil karbonil spojem i karbonatnom bazom u bifaznom sustavu otapala da se proizvede prečišćeni spoj 8; i
The composition according to claim 7, wherein the granules have a granule D50 measured using a sieve analysis ranging from about 50 um to about 150 um. 
Smjesa prema zahtjevu 10, gdje granule imaju Dsg izmjeren pomoću analize sitom u rasponu od 50 um do 150 um, poželjno od 80 um do 130 um.